Skip to main content

What are you looking for?

Write the name, title or any keyword related to what you are looking for and select which content category it belongs to.

Estudio de fase II, aleatorizado, doble ciego, controlado con placebo y de búsqueda de dosis para evaluar la eficacia y la seguridad de psireotida s.c en pacientes de hipoglucemia posbariatrica.

  • Protocol code: SOM230-RECAG-CL-0576
  • EudraCT code: No aplica
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Ciudin Mihai, Andreea
  • Research group:  Diabetis i metabolisme
  • Service: Endocrinologia
  • Phase: Fase II
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Phase 3 randomized, placebo-controlled, double-blind, multicenter study to evaluate the efficacy and safety of nipocalimab in pregnancies at risk for severe hemolyticdisease of the fetus and newborn (hdfn) - azalea

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 DoseLevels of NMD670 over 21 Days in Adult Patients with AChR/MuSK-Ab+Myasthenia Gravis'

  • Protocol code: NMD670-02-0002
  • EudraCT code: No aplica
  • Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified
  • Principal investigator:  Juntas Morales, Raul
  • Research group:  Sistema nerviós perifèric
  • Service: Neurologia
  • Phase: Phase II
  • Recruiting: Closed
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

ESTUDIO DE FASE IIIb, GLOBAL, MULTICÉNTRICO, ALEATORIZADO, CON ENMASCARAMIENTO PARA EL EVALUADOR VISUAL, PARA EVALUAR LA EFICACIA, SEGURIDAD Y FARMACOCINÉTICA DE RANIBIZUMAB ADMINISTRADO CON EL DISPOSITIVO “PORT DELIVERY SYSTEM” UTILIZANDO UNA PAUTA DE RECARGA CADA 36 SEMANAS, EN PACIENTES CON DEGENERACIÓN MACULAR ASOCIADA A LA EDAD NEOVASCULAR (VELODROME)

  • Protocol code: WR42221
  • EudraCT code: 2020-001313-20
  • Pathology: Malalties de l’ull i dels seus annexos
  • Principal investigator:  García Arumí, José
  • Research group:  Oftalmologia
  • Service: Oftalmologia
  • Phase: Phase III
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio aleatorizado, doble ciego, comparado con placebo y multicéntrico de lumateperona como terapia complementaria en el tratamiento de pacientes con trastorno depresivo mayor

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.
Year
2024
Títol Complet
Servicio de adquisición de imágenes de resonancia magnética de alto campo (7.0 T) en modelo animal, a cargo del Proyecto PI22/01709 del Grupo de Neurorradiologia de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR).
Expedient
RESONANCIA MAGNÉTICA ALTO CAMPO (PI22/01709)
Codi
24972560
Data publicació
Year
2024
Títol Complet
Contractació dels serveis d’auditoria externa per evidenciar el nivell de compliment dels requisits del Sistema de Gestió de la Qualitat ISO 9001:2015, de la plataforma Functional Validation & Preclinical Research (FVPR) del Grup Clinical Biochemistry-Drug Delivery & Therapy (CB-DDT) de la Fundació Hospital Universitari Vall d’Hebron - Institut de Recerca (VHIR).
Expedient
AUDITORIA EXTERNA FVPR
Codi
24972370
Data publicació
Year
2024
Títol Complet
Compra de una licencia y migración de datos para la gestión integral de donantes y muestras del Biobanco, a cargo del Proyecto PT20/00107 del Biobanco de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR).
Expedient
LICENCIA GESTIÓN INTEGRAL DONANTES Y MUESTRAS (PT2
Codi
24972155
Data publicació
Year
2024
Títol Complet
Acuerdo Marco para el contrato de servicio de asesoramiento legal y estrategico en materia de innovación, propiedad industrial e intelectual y/o creación de empresas basadas en el conocimiento destinado a la Dirección de Innovación y Desarrollo de Negocio de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR).
Expedient
AM ASESORAMIENTO LEGAL Y ESTRATEGICO
Codi
24972276
Data publicació
Year
2024
Títol Complet
Servicios para llevar a cabo la realización y lectura de resonancias magnéticas, a cargo del Proyecto 202234-32, destinado al Grupo de Psiquiatría, Salud Mental y Adicciones de la Fundació Hospital Vall Hebron- Institut de Recerca (VHIR).
Expedient
SERVICIO RM (202234-32)
Codi
24972154
Data publicació
Year
2024
Títol Complet
Servicios para llevar a cabo las cardio-resonancias magnéticas CMR con contraste a los pacientes (con criterios de inclusión) de todos los centros que participan en el estudio cardiovascular toxicity in early human epidermal growth factor receptor-2 -positive breast cancer (herbca): from risk evaluation to prevention a cargo del Projecte la Fundació de la Marató de TV3 -10, destinado al Área de Enfermedades Crónicas, prevalentes y envejecimiento - Institut de Recerca (VHIR).
Expedient
SERVICIO RMC PROYECTO 202311-10 Marató.
Codi
24972094
Data publicació

Professionals

Sara Lopez Gonzalez

Professionals

Maria Alvarez de Toledo López

Metgessa resident de Pediatria a l'Hospital Vall d'Hebron, amb especial interès al camp de la Infectologia Pediàtrica i les Immunodeficiències.